1. ZHAW digitalcollection
  2. Life Sciences und Facility Management
  3. Publikationen
  4. Publikationen Life Sciences und Facility Management
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFischer, Thomas-
dc.contributor.authorRiedl, Rainer-
dc.date.accessioned2021-02-25T08:31:10Z-
dc.date.available2021-02-25T08:31:10Z-
dc.date.issued2020-09-14-
dc.identifier.issn1746-0441de_CH
dc.identifier.issn1746-045Xde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/21834-
dc.description.abstractMatrix metalloproteinases have been in the scope of pharmaceutical drug discovery for decades as promising targets for drug development. Until present, no modulator of the enzyme class survived clinical trials, all failing for various reasons. Nevertheless, the target family did not lose its attractiveness and there is ever more evidence that MMP modulators are likely to overcome the hurdles and result in successful clinical therapies.de_CH
dc.language.isoende_CH
dc.publisherTaylor & Francisde_CH
dc.relation.ispartofExpert Opinion on Drug Discoveryde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectAntibodiesde_CH
dc.subjectDrug designde_CH
dc.subjectDrug discoveryde_CH
dc.subjectHemopexin-like domainde_CH
dc.subjectMatrix metalloproteinasede_CH
dc.subjectMedicinal chemistryde_CH
dc.subjectPolypharmacologyde_CH
dc.subjectSmall-molecule inhibitorsde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.titleChallenges with matrix metalloproteinase inhibition and future drug discovery avenuesde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.1080/17460441.2020.1819235de_CH
dc.identifier.pmid32921161de_CH
zhaw.funding.euNode_CH
zhaw.issue1de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end88de_CH
zhaw.pages.start75de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume16de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedCC Drug Discoveryde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.
Show simple item record
Fischer, T., & Riedl, R. (2020). Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opinion on Drug Discovery, 16(1), 75–88. https://doi.org/10.1080/17460441.2020.1819235
Fischer, T. and Riedl, R. (2020) ‘Challenges with matrix metalloproteinase inhibition and future drug discovery avenues’, Expert Opinion on Drug Discovery, 16(1), pp. 75–88. Available at: https://doi.org/10.1080/17460441.2020.1819235.
T. Fischer and R. Riedl, “Challenges with matrix metalloproteinase inhibition and future drug discovery avenues,” Expert Opinion on Drug Discovery, vol. 16, no. 1, pp. 75–88, Sep. 2020, doi: 10.1080/17460441.2020.1819235.
FISCHER, Thomas und Rainer RIEDL, 2020. Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opinion on Drug Discovery. 14 September 2020. Bd. 16, Nr. 1, S. 75–88. DOI 10.1080/17460441.2020.1819235
Fischer, Thomas, and Rainer Riedl. 2020. “Challenges with Matrix Metalloproteinase Inhibition and Future Drug Discovery Avenues.” Expert Opinion on Drug Discovery 16 (1): 75–88. https://doi.org/10.1080/17460441.2020.1819235.
Fischer, Thomas, and Rainer Riedl. “Challenges with Matrix Metalloproteinase Inhibition and Future Drug Discovery Avenues.” Expert Opinion on Drug Discovery, vol. 16, no. 1, Sept. 2020, pp. 75–88, https://doi.org/10.1080/17460441.2020.1819235.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.